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The solid state forms of the sex hormone 17-β-
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Erin L. Stevenson,a Robert W. Lancaster,a Asma B. M. Buanz, b Louise S. Price, a
Derek A. Tocher a and Sarah L. Price *a
The crystal structure of the single component form of the primary female sex hormone, 17-β-estradiol
(BES), is reported, solved from single crystals obtained by sublimation. The Z′ = 2 P212121 structure was
computationally predicted as one of the thermodynamically plausible structures. It appears that the dehy-
dration process for the very stable hemihydrate structure is a complex process, strongly affected by particle
size and conditions. An experimental polymorph screen has produced six solid forms of BES, including novel
acetonitrile and highly labile ethylene dichloride solvates, and reproduced previously reported methanol and
propanol solvates. These have been characterized, as far as possible given the metastability relative to the
hemihydrate (BES·0.5H2O), by single-crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), dif-
ferential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hot-stage microscopy and Fourier
transform infrared spectroscopy (FT-IR), sorting out some of the confusion in the earlier literature.
Introduction
Solvent molecules (including water) commonly satisfy the hy-
drogen bonding sites of an organic molecule better than the
molecule itself. Therefore, organic molecules often crystallize
as solvated or hydrated solid forms, in which solvent or water
molecules occupy a regular position within the crystal
structure.1–3 The presence of a solvent molecule in the crystal
packing arrangement plays a critical role in the activity of a
drug by altering the intermolecular interactions within the
solid. This can modify the internal energy and enthalpy and
therefore affect pharmaceutically important properties such
as solubility and bioavailability.1,4 Most frequently, hydrates
are less soluble than the corresponding anhydrate leading to
a possibly undesirable decrease in bioavailability.4 Therefore,
it is of great interest to the pharmaceutical industry to iden-
tify and understand any interconversions between solid
forms. This can be particularly demanding for hydrates, as
water is difficult to exclude from a process but simple hydrate
classifications can be inappropriate for pharmaceutical devel-
opment.5 The control of production of crystalline products,
which may be very sensitive to water activity in crystallization,
filtration and drying processes, is essential in order to manu-
facture pharmaceutical material fit for purpose.6
The studied estrogen, 17-β-estradiol (BES), is a white,
odourless powder that is a primary female sex hormone asso-
ciated with the female reproductive system. It is widely used
in hormone replacement therapy for the treatment of post-
menopausal symptoms, hormonal contraception and the
treatment of hormone sensitive cancers.7,8 It is marketed as
the hemihydrate form which in terms of pharmacodynamics
is identical to the anhydrous form.9 However, the hemihy-
drate is significantly less soluble and has a lower oral bio-
availability.10 It therefore needs to be micronized or esterified
in order to be bioavailable to any significant extent.11 Re-
markably for such an important pharmaceutical, there are no
crystal structures containing just BES in the Cambridge Struc-
tural Database (CSD).12
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Busetta et al.13 determined the full crystal structure of
BES·0.5H2O in 1972 (CSD Refcode ESTDOL10). The water mol-
ecules are located on the 2-fold axis and participate in hydro-
gen bonding to the hydroxyl groups on the A- and D-rings
(Fig. 2). Differential thermal analysis (DTA) by Florence
et al.,14 in 1975, shows that BES·0.5H2O exhibits endothermic
peaks around 112 °C and 174 °C prior to the melting endo-
therm at 179 °C. Analysis of the effluent gas of DSC samples
by Kuhnert-Brandstätter et al.,15 in 1976, showed that these
pre-melting endotherms are associated with water loss.
Thermomicroscopic examination by the same group suggests
that there is some structural rearrangement of BES·0.5H2O be-
fore melting. It was therefore concluded by Salole,16 in 1987,
that BES·0.5H2O dehydrates in two stages. The first stage is
around 112 °C, and the second at ca. 174 °C, which results in
the complete loss of water and transformation to an anhy-
drous form before melting. There appears to be no obvious ex-
planation from examining the crystal structure (Fig. 2) as to
why water is lost in two stages. Florence et al.14 also observed
that after grinding BES·0.5H2O there is no change in the IR
spectrum, however the DTA curve contains only a single en-
larged pre-melting endotherm around 120 °C. This change
suggests that BES·0.5H2O is partially dehydrated upon grind-
ing and an anhydrous form can be obtained at temperatures
about 60 °C lower than a sample that has not been ground. In
2000, Variankaval et al.17 investigated the release of water
from BES·0.5H2O near the melting point by DSC to find the
compete removal of water only occurred after the sample had
melted, apparently contradicting the work mentioned above.
Smakula et al.18 first identified four different crystalline
forms and one amorphous form of BES (BES(am)) in 1957, by
IR absorption spectroscopy and X-ray powder diffraction. The
IR spectra of the two anhydrous crystalline forms (BES Form
I and BES Form II) suggested that BES Form I contained an
O–H group not involved in hydrogen bonding and that in
BES Form II there was ketonization of the steroid A-ring. The
other two crystalline forms that Smakula described as anhy-
drous have been identified by Salole16 as BES·0.5H2O and the
methanol hemisolvate (BES·0.5MeOH). Heating of any of the
four forms between two rock salt plates produces a common
glassy amorphous form, BES(am).
About the same time, Kuhnert-Brandstätter et al.19 inde-
pendently concluded that 17-β-estradiol anhydrate is dimor-
phic from the thermomicroscopy of cooled melts and postu-
lated that BES Form I is the more stable. They also showed
that desolvation of BES·0.5H2O usually transforms to BES
Form I. Variankaval et al.17 prepared BES Form I from slow
cooling a melt of BES·0.5H2O, and prepared BES Form II
from dissolving BES·0.5H2O in ethyl acetate followed by evap-
oration to dryness from boiling. The DSC analysis of these
two forms showed that BES Form I had one melting endo-
therm around 178 °C, and BES Form II showed two endo-
therms, one at a lower temperature appearing as a shoulder
on the other at 178 °C. This suggests that BES Form I and
BES Form II are often found in mixtures or BES Form II con-
verts to BES Form I prior to melting. The difficulty in
obtaining BES Form II is cited in all three publications and
there is little crystallographic evidence to prove that BES
Form II is a polymorph of 17-β-estradiol, with the molecular
structure shown in Fig. 1.
The ability of 17-β-estradiol to form solvates with organic
solvents has been shown by Busetta et al.20 who published an
orthorhombic propanol monosolvate (BES·PrOH, refcode
ESTRDP) in 1972. In 1999, Parrish et al.21 published a tri-
clinic methanol hemisolvate (BES·0.5MeOH, refcode BEQJIQ).
The presence of an ethanol solvate was proposed by
Resetarits et al.22 in 1978. Variankaval et al.17 performed ther-
mal analysis on BES·0.5MeOH showing two weight loss peaks
in the TGA and two pre-melting endotherms in the DSC. This
suggests that BES·0.5MeOH loses methanol from the crystal
structure in two stages, similar to the behaviour of BES·0.5H2O
and the proposed ethanol monosolvate.22 A mixed solvate
(BES)3ĲMeOH)2ĲH2O) (WURWEL) has also been reported.
23
The most characteristic property of 17-β-estradiol is its ten-
dency to crystallize as BES·0.5H2O, in which it precipitates
not only from aqueous solution, but also from ethyl acetate,
chloroform, absolute ethanol and other supposedly anhy-
drous solvents.16 This may explain why the PXRD patterns
presented24 for four different solvate forms of 17-β-estradiol
are so extremely similar to that for BES·0.5H2O that it is likely
that only BES·0.5H2O was obtained in these cases.
This history inspired us to perform a polymorph screen
on BES, particularly seeking to characterize the anhydrous
BES forms. Anticipating that the structureĲs) would have to
be solved from PXRD, a simultaneous crystal structure pre-
diction (CSP) study was performed.
Experimental
Materials
Enantiopure 17-β-estradiol hemihydrate (BES·0.5H2O) was
obtained as a white microcrystalline powder from Sigma Co.
17-β-estradiol anhydrate (BES Form I) was prepared by
heating the hemihydrate up to 150 °C for four hours.
Fig. 2 Packing diagram (projection down the a axis) for BES·0.5H2O.
Location of water on a two-fold axis is illustrated. Blue lines indicate
hydrogen bonding, with the through-molecule Chain 1 horizontal and
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Methods
Crystallization. Solvent crystallization experiments
encompassed slow evaporation, evaporation to dryness from
boiling solvents, cooling crystallization (various cooling rates)
and sublimation under vacuum.
Slow evaporation crystallization experiments were carried
out by dissolving either microcrystalline BES·0.5H2O (∼10 mg
or ∼5 mg) or anhydrous BES (∼10 mg or ∼5 mg) in various
solvents (∼3 mL) in small sample tubes and left at ambient
temperature or 5 °C. The vessels were either uncapped or
had 4 holes punched into the lids. Samples prepared from
anhydrous BES were placed in a P2O5 filled desiccator. Experi-
ments involving evaporation to dryness from boiling solvent
were carried out by dissolving microcrystalline BES·0.5H2O
(∼30 mg) in ethyl acetate (∼6 mL) and heating on a hot plate
until dryness was achieved. Cooling crystallization experi-
ments were undertaken by heating microcrystalline
BES·0.5H2O (∼10 mg) to a temperature above the melting
point of 178 °C or to 150 °C for an extended period and sub-
sequent slow cooling at various rates to RT. Sublimation ex-
periments were performed by sealing a small amount of
microcrystalline BES Form I (∼100 mg) in Pyrex tubing at ap-
proximately 5 × 10−2 mmHg and heating in a tube furnace
with a temperature gradient of 150 to 25 °C. Further details
of all crystallization techniques attempted and solid forms
produced are provided in the ESI† (Part A section 1).
Infrared spectroscopy. IR was performed using a Perkin
Elmer Spectrum One, FT-IR spectrometer. Data were collected
using the Spectrum software (version 5.3.1). All IR spectra are
available in the ESI† (Part A section 2).
Powder X-ray diffraction. Capillary powder X-ray diffrac-
tion data were collected for phase identification using a Stoe
StadiP capillary geometry system using monochromatic CuKα
radiation (λ = 1.5406 Å) and 2θ scans were measured at RT
from 2.000° to 45.065° in 0.495° steps with 5.0 s per step or
30.0 s per step for improved signal to noise ratio. The sam-
ples were lightly ground using an agate pestle and mortar
and loaded into a 0.7 mm diameter borosilicate capillary that
was subsequently sealed. The samples were aligned with a wide
collimator using Faceit (Video) X.view software (version 2.14).
Single crystal X-ray diffraction. Single crystals were mea-
sured at 150 K or 160 K using monochromatic CuKα radia-
tion (λ = 1.5406 Å) and mounted on a nylon loop on an
Agilent Super Nova, Dual, Cu at zero, Atlas diffractometer.
Using Olex2,25 structures were solved with ShelXS26 structure
solution program using direct methods and refined with the
ShelXL27 refinement package using least-squares minimiza-
tion. All PXRD and SCXRD data can be found in the ESI†
(Part A section 3).
Thermal analysis. Hot stage microscopy was used to moni-
tor changes in BES·0.5H2O and BES(am) upon heating. The
samples were observed from 25 to 195 °C on a Reichert (Aus-
tria) Kofler hot stage microscope. TGA measurements were
performed on a Discovery TGA (TA instruments, LLC, Waters,
USA). Open TA aluminium pans were used with sample mass
of about 5 mg and samples were heated at 10 °C min−1 from
20 to 200 °C in dry nitrogen (flow rate of 25 mL min−1). Data
collection and analysis were performed with TA Trios soft-
ware (version 3.3.0.4055) and mass loss reported as weight
percentage (% w/w). DSC experiments were performed on a
Q2000 DSC instrument (TA Instruments, LLC, Waters, USA).
Temperature and cell constant calibration was performed
with certified indium (Tm = 156.6 °C and 28.72 J g
−1) and
data were collected with TA Advantage software (version
5.5.3). Tzero aluminium pans were used with a single hole
punched into the lid and with a sample mass of about 5 mg.
Samples were heated at 10 °C min−1 from 20 to 200 °C in dry
nitrogen (flow rate of 50 mL min−1). Peak integration was
performed with the sigmoidal integration function in TA Uni-
versal Analysis software (version 4.5A) and temperatures are
reported as extrapolated onset and/or peak values.
Computational methods. The crystal structures were
modelled by the Ψmol approach
28 of separating the lattice en-
ergy (Utot) into the sum of the intermolecular interactions
within the crystal (Uinter) and the conformational energy pen-
alty for the conformational changes in the molecule from the
most favourable isolated molecule structure (ΔEintra).
28 Two
separate CrystalPredictor2.2 (ref. 29) searches were carried
out, with the hydroxyl group C4–C3–O1–H23 varying by up to
10° from either planar position, and the C13–C17–O2–H24
angle being a search variable. The searches had two indepen-
dent molecules (Z′ = 2), since large chiral compounds have a
greater tendency to form Z′ > 1 structures,30 and covered the
most common chiral space groups (P1, P21, P21212, P212121,
C2, C2221, P41, P43, P41212, P43212, P31, P32, R3, P3121, P3221,
P3221, P61, P63, P213 and P2221). Following removal of
duplicate structures, all structures within 15 kJ mol−1 of the
lowest energy structure (∼3500) were minimized with
CrystalOptimizer.31 Within this program, the intramolecular
energy, ΔEintra, was evaluated using GAUSSIAN at the PBE0/6-
31G(d,p) level of theory, the charge density was evaluated at
the same level of theory, the distributed multipole analysis32
was carried out with GDMA2.2. These atomic multipoles were
used to model the electrostatic contribution to Uinter, and
combined with the FIT repulsion–dispersion potential,33,34 to
model the intermolecular lattice energy of the crystal struc-
ture, Uinter, using DMACRYS.
35
The stability of anhydrous BES was compared to that of
BES·0.5H2O and other solvates by minimizing the solvates
with the same CrystalOptimizer computational model and
comparing the lattice energies of Utot (BES) and Utot (ice/sol-
vent) with Utot (BES·0.5H2O/solvate) in the appropriate ratios
relative to one mole of BES.36 Full details of the computa-
tional methods are in Part B of the ESI.†
Results
Structural studies
Hemihydrate (BES·0.5H2O). Single crystals of 17-β-estradiol
hemihydrate (BES·0.5H2O) were obtained by slow evaporation
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BES·0.5H2O in the solvents ethanol, acetonitrile, ethyl ace-
tate, diethyl ether, acetone, isopropanol, n-butanol, isopropyl
ether, n-butyl ether and methanol. No alternative solvates
were isolated via this method. The single crystal used for
X-ray diffraction was obtained from ethanol. Structure solu-
tion and refinement were consistent with the CSD structure,
ESTDOL10,13 although the new structure is of higher quality
(Part A section 3.1 of the ESI†). Lattice parameters for crystals
isolated from ethyl acetate and acetonitrile were measured
and found to be sufficiently similar to BES·0.5H2O isolated
from ethanol that they are assumed to be the same structure.
The IR spectra for all other crystals grown from the
remaining solvents were identical to the spectrum of
BES·0.5H2O isolated from ethanol and so are assumed to be
the same form.
Methanol Hemisolvate (BES·0.5MeOH). Single crystals of
17-β-estradiol methanol hemisolvate (BES·0.5MeOH) were
obtained by dissolving microcrystalline BES·0.5H2O in analyt-
ical grade methanol followed by slow evaporation (approxi-
mately 2 weeks). Single crystal X-ray data were collected for
BES·0.5MeOH. The data were solved and refined to give lower
R values than the previously reported crystal structure of the
methanol solvate, CSD BEQJIQ21 (see Part A section 3.1 of the
ESI†).
Anhydrous forms of 17-β-estradiol. The screening found
(ESI† Part A section 1.3) amorphous BES(am) and microcrystal-
line BES Form I by a variety of methods, including the litera-
ture procedures. Single crystals of BES Form I could only be
obtained by sublimation. A few slow evaporation methods
from ethyl acetate and diethyl ether gave an IR spectrum
which, in addition to the Form I peaks, had a peak at 1734
cm−1 indicative of a ketone group. This is consistent with the
literature suggestion18 that Form II contains the keto form
and so is not strictly a polymorph. If these samples contained
Form II, it was so metastable that further characterization
was not possible.
Amorphous 17-β-estradiol (BES(am)). Amorphous 17-β-
estradiol (BES(am)) was produced by heating microcrystalline
BES·0.5H2O to 185 °C for 1–2 h, then cooling to room tem-
perature at 1 °C min−1. The non-crystalline glass solid has an
IR spectrum with a broad peak around 3314 cm−1 corre-
sponding to disordered O–H stretching vibrations of the hy-
droxyl groups. The PXRD pattern shows only a single broad
peak, confirming the amorphous nature of the material (Fig.
S3 and S5 of the ESI†).
Anhydrous 17-β-estradiol (BES Form I). Anhydrous 17-β-
estradiol (BES Form I) was prepared by each of the following
methods: evaporation to dryness from a boiling ethyl acetate
solution of BES·0.5H2O, heating microcrystalline BES·0.5H2O
to 150 °C or 185 °C for 4 or 2 hours respectively and subse-
quent cooling to RT at an uncontrolled rate, and heating
BES(am) to 140 °C for 10 min. Each of these procedures
resulted in formation of a white crystalline powder. Single
crystals of BES Form I were produced by sublimation of
microcrystalline BES Form I under vacuum for 1 week. The
IR spectrum of BES Form I gives rise to a strong sharp peak
at 3527 cm−1 corresponding to a stretching vibration of an
O–H group not involved in hydrogen bonding (a free OH).
Analytical data (IR spectroscopy, PXRD and DSC analysis) was
identical for each of the preparative methods. Single crystal
X-ray diffraction data were collected for BES Form I prepared
by sublimation under vacuum (Fig. 3, ESI† Part A section
3.1).
BES Form I crystallizes in the orthorhombic space group
P212121 with Z′ = 2. Layers of estradiol molecules of the same
symmetry equivalence are formed by translation along the a
and b axes (green in Fig. 3). Between these layers, estradiol
molecules of the other symmetry equivalence (blue in Fig. 3)
are hydrogen bonded to the layers through the hydroxyl
group on the D-ring forming ladder-like packing.
Alternative 17-β-estradiol solvate forms. In order to isolate
alternative polymorphs of anhydrous 17-β-estradiol, micro-
crystalline BES Form I was dissolved in dry solvents and slow
evaporative techniques were performed in a P2O5 filled desic-
cator. This was an attempt to remove water and prevent the
crystallization of the prevalent BES·0.5H2O, but only solvate
forms were isolated.
17-β-estradiol n-propanol solvate (BES·PrOH). Single crys-
tals of 17-β-estradiol n-propanol solvate (BES·PrOH) were pro-
duced by dissolving microcrystalline BES Form I in anhy-
drous n-propanol, followed by slow evaporation in a P2O5
filled desiccator. Single crystal X-ray diffraction data were col-
lected and were consistent with the previously reported struc-
ture, CDS reference ESTRPD,20 albeit the new determination
is of better accuracy (ESI† Part A section 3.1). BES·PrOH crys-
tallizes in the orthorhombic space group P212121 with Z′ = 1.
There is one complete molecule of propanol in the asymmet-
ric unit. The propanol molecules are involved in a hydroxyl-
only (Chain 2, ESI† Fig. S17) hydrogen bonding chain along
the a direction bridging the hydroxyl group on the A-ring of
Fig. 3 Packing diagram of BES Form I, molecules coloured by
symmetry equivalence. Chain 1 through-molecule hydrogen bonding
runs vertically through the green molecules, and the hydroxyl Chain 2
is perpendicular to the page linking each blue molecule with two adja-
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one estradiol molecule and the hydroxyl group on the D-ring
of another.
17-β-estradiol ethylene dichloride solvate, (BES·EDC). Sin-
gle crystals of 17-β-estradiol ethylene dichloride solvate
(BES·EDC) were produced by dissolving microcrystalline BES
Form I in anhydrous ethylene dichloride, followed by slow
evaporation in a P2O5 filled desiccator. Single crystal X-ray
diffraction data were collected for BES·EDC, which suggested
that it was isomorphous with BES·PrOH. However, the com-
pleteness of the reflection data was not sufficient and the
model obtained was not close to a minimum in the lattice en-
ergy with the computational model used (ESI† Table S7) and
appeared to be very unstable relative to dissociation. Re-
peated attempts to grow single crystals failed to provide a
better single crystal, leading to the conclusion that BES·EDC
is a highly labile solvate.
17-β-estradiol acetonitrile solvate (BES·ACN). Single crys-
tals of 17-β-estradiol acetonitrile solvate (BES·ACN) were pro-
duced by dissolving microcrystalline BES Form I in anhy-
drous acetonitrile, followed by slow evaporation in a P2O5
filled desiccator. Single crystal X-ray diffraction data were col-
lected for BES·ACN (Fig. 4, ESI† Part A section 3.1). BES·ACN
crystallizes in the chiral orthorhombic space group P212121
with Z′ = 1. There is one full acetonitrile molecule in the
asymmetric unit, which is hydrogen bonded to the estradiol
(Fig. 4 top).
Thermal analysis
BES·0.5H2O. Smakula et al.
18 reported that anhydrous BES
could be isolated by heating BES·0.5H2O to a temperature be-
tween 95 °C and 170 °C and in this study heating BES·0.5H2O
to 150 °C for 4 hours also isolated BES Form I.
Heating a microcrystalline sample of BES·0.5H2O on a hot
stage microscope led to droplets of water appearing around
168–170 °C associated with the onset of melting which was
completed at 180 °C. On cooling, amorphous BES was ob-
served on the microscope slide. Sublimation occurred onto
the cover slide to give a white crystalline powder with the
same IR spectrum as BES Form I. In single crystal form,
heating BES·0.5H2O did not show any droplets of water
appearing before melting began at 175 °C.
DSC analysis of BES·0.5H2O as a microcrystalline powder
shows two pre-melting endotherms, at 114–140 °C and 173.5
°C, before the melt at 179 °C (Fig. 5a). TGA analysis indicated
that the first endothermic peak corresponds to a partial loss
of water (1.2% of mass) and the second completes a total
weight loss of 3.5% (Fig. 5b). DSC analysis of Form
BES·0.5H2O in single crystal form gives rise to a single pre-
melting endotherm at 173.5 °C and a melting endotherm at
178.5 °C (Fig. 5a). The TGA analysis indicates that the there
is a gradual loss of 0.7% of mass, probably reflecting subli-
mation, before the pre-melting endotherm corresponding to
complete loss of water (Fig. 5c). Thus, the loss of water is very
different between the crystalline powder and as a single
crystal.
The stability of BES·0.5H2O was also examined in the pres-
ence of the dehydrating agent, P2O5, in a sealed desiccator.
After 6 weeks, the sample remained as a white microcrystal-
line powder. The IR spectrum (ESI† Fig. S1) gives rise to a
small additional peak around 3600 cm−1 which might corre-
spond to a slight rearrangement in the solid resulting in
some non-hydrogen bonded O–H groups, however the PXRD
analysis (ESI† Fig. S4) shows no significant structural change.
The DSC analysis of this material shows one main pre-
melting endothermic peak at 173.5 °C, (ESI† Fig. S7)
suggesting that the water that would normally be released
around 113–142 °C has been removed by the drying agent.
There is a small broad endothermic peak between ∼80 and
120 °C (ESI† Fig. S7) indicating that part of the water has
been removed by the drying over the desiccant but it was not
completely removed. This is consistent with the TGA analysis
(ESI† Fig. S7) showing two stages of water loss, the first at
80–94 °C, comprising 1.3% weight loss, and the second at
171–176 °C, with the total loss of water being 3.5% weight.
The first loss of water occurs at a lower temperature than for
the hemihydrate starting material, suggesting that the P2O5
drying agent affects the water binding. Throughout the TGA
analyses of the desolvation, the final mass loss was somewhat
greater than the stoichiometric 3.2%, in the range 3.5–4.0%,
probably due to a mixture of sublimation and surface water
loss. Hence, overall the dehydration of BES·0.5H2O is very de-
pendent on the conditions.
Fig. 4 (top) Packing diagram of BES·ACN, viewed down the a axis.
(bottom) Hydrogen bonding between the estradiol hydroxyl groups
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Other forms. The thermal analysis of the other solvates
shows that there is another apparently two-step process for
MeOH (ESI† Fig. S10a) and that BES·ACN (ESI† Fig. S10b)
and BES(am) (ESI† Fig. S9) show multiple weight loss events.
Fig. 6 summarizes the established solid forms and
interconversions.
Computational results
The CSP search generated a range of low energy structures
(Fig. 7), which have been categorized by the conformation of
the C3–O1–H hydroxyl group and the hydrogen bonding mo-
tif. The experimentally observed anhydrous BES Form I struc-
ture was found about 4 kJ mol−1 above the global minimum.
This relative stability is predominantly from the steroid back-
bone packing as the structure has unsatisfied hydrogen
bonding of half the O1 hydroxyl groups. The OH⋯OH⋯OH
chain structure (Chain 2) does appear in the water and alco-
hol solvates with the solvent OH in every 3rd or 5th place.
Given the size of the molecule and unit cells, the differ-
ences in the hydrogen bonding and range of densities, and
the neglect of thermal effects by considering lattice rather
than free energy, the observed Form I could be the thermody-
namically most stable within computational error. However,
it is unlikely that none of the other structures are thermody-
namically plausible as polymorphs.
All the potential polymorphs of BES were calculated to be
very unstable relative to the hemihydrate (Fig. 8).
Discussion
17-β-estradiol has an experimentally diverse solid form land-
scape composed of one anhydrous form, one hemihydrate,
one methanol hemisolvate, two monosolvates (ACN, PrOH)
and an amorphous form. We found a highly labile, metasta-
ble ethylene dichloride solvate but no evidence of the previ-
ously proposed ethanol solvate.22 This may be a limitation of
our range of experiments, as different alcohols could occupy
the interlayer spacing (Fig. 9), as in the family of alcohol sol-
vates of a pharmaceutical salt.37 The formation of the highly
elusive Form II probably involves a transformation of some
molecules to the keto-tautomer. It has been established that
BES·0.5H2O is the most commonly found crystal form and
BES Form I will only crystallize when water or other solvent
Fig. 5 DSC and TGA traces of BES·0.5H2O. (a) DSC curve of a
crystalline powder (black) and a single crystal (red). (b) TGA curve of a
crystalline powder (black) including derivative with respect to time
(red). (c) TGA curve of a single crystal form.
Fig. 6 Summary of methods of interconversion between solid forms
found in this project. Green denotes solid forms newly discovered in
this work, blue denotes previously identified solid forms which we
have been able to verify, and red denotes those in the literature which
we have not verified. Shaded forms are those for which there is
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molecules are rigorously excluded. The structure of this anhy-
drous form has been unambiguously established by single
crystal X-ray diffraction. While a good deal of crystallization
space has been explored, it nevertheless remains likely that
many other undiscovered solid forms may still be found,
such as mixed solvates exemplified by (BES)3ĲMeOH)2ĲH2O)
(WURWEL).23 There are many more possibilities for multi-
component complexes such as that formed with urea
(ESOURE10)38 and recently, formamide.39,40 The extension to
co-crystallization with larger molecules has been partially in-
vestigated, with cocrystals with isonicotinamide (ULUFIS)
and piperazine dihydrate (ULUFOY) being reported from a
search for increased solubility,41 and with pyrene (CUTBEZ),
phenanthrene (RUGYID), benzo[h]quinoline (RUFYIC) and
1,2-dimethylnapthalene (RUFOY) in investigations of the mo-
lecular recognition of steroids.42,43 The crystal energy land-
scape (Fig. 7) suggests that other polymorphs of BES are
highly likely, although Form I may well be the most thermo-
dynamically stable form given the accuracy of the
calculations.
Single crystal X-ray diffraction studies demonstrate that
there are clear similarities in the arrangement of BES mole-
cules in many of the structures. While the hemihydrate is not
isomorphous with the propanol solvate, the water molecule
occupies a similar position between the same hydrogen
bonding chain (Chain 1) and plays a similar role in the crys-
tal structures. The crystal structure of anhydrous BES Form I
also contains a similar through-molecule hydrogen bonding
Chain 1 arrangement of BES molecules, however the rows are
now further apart as the sites previously occupied by solvent
are occupied by a second set of BES molecules, approximately
orthogonal and doubly hydrogen-bonded through a single ox-
ygen atom (Chain 2), linking the through-molecule (Chain 1)
motifs (Fig. 9).
Fig. 7 Summary of the CSP study of BES. Each point corresponds to a structure which is a lattice energy minimum, calculated with the Ψmol
method with intramolecular energy and charge density evaluated at the PBE0/6-31G(d,p) level and the FIT repulsion–dispersion model being used
for the other terms. The structures have been categorized by motif X:nm:al where XA or B denotes the O1H23 proton conformation; nm
denotes the Chain 1 through-molecule hydrogen bonding type, with n denoting whether 1 or 2 molecules (of the Z′ = 2 molecules in the structure)
are involved in through molecule hydrogen bonding and m denoting whether O1, O2 or both are acting as hydrogen bond donor; al denotes the
Chain 2 hydroxyl-only hydrogen bonding type, n denotes that this is not present, c is that it is a chain, d a discrete interaction and r that it is a ring,
the number l describes the order of the donor atoms along the hydroxyl only hydrogen bond motif as defined in ESI† Fig. S17.
Fig. 8 Relative stability of solvates, compared to BES Form I. The error

























































































CrystEngComm This journal is © The Royal Society of Chemistry 2018
Throughout the solid form screening experiments, it is ev-
ident that when water is available BES·0.5H2O will preferen-
tially crystallize. The dominance of this form can be
explained by the clear calculated relative stability of
BES·0.5H2O over even the other stable solvates such as
BES·0.5MeOH (Fig. 8). Experimentally, the crystallization of
BES·0.5MeOH is significantly kinetically favoured over the
remaining solid forms which take much longer to nucleate,
thus BES·0.5MeOH can be isolated with a lesser degree of
control than the other solvates. This highlights a key limita-
tion of the computational model of Fig. 8 (ESI† Table S7)
which is based purely on predicting thermodynamic stability
of structures.44 The kinetics of crystallization are scarcely un-
derstood but are potentially the main factors in determining
which solid forms are experimentally obtained,45 particularly
in this case where the kinetically and thermodynamically
favoured solid form is a hydrate. The prevalence of
BES·0.5H2O is practically linked to the difficulty in removing
water from organic solvents, and avoiding accidental seeding
with the BES·0.5H2O starting material.
46
All attempts to produce single crystals of the anhydrous
form(s) from nominally anhydrous solvents using microcrys-
talline anhydrous BES were unsuccessful. In our hands each
of these experiments led to a transformation to the corre-
sponding solvate or the hydrate (presumably by the
unintended inclusion of water from the solvent or atmo-
sphere). It appears that it is more favourable for the 17-β-
estradiol molecules to pack with the available solvents as op-
posed to just with themselves, despite Form I and other
computer-generated structures having a reasonable packing
density.
The mechanism of desolvation of BES·0.5H2O is unclear.
Although there is a common chain that is preserved, the
rearrangement of half the BES molecules to substitute for the
solvent linkages between the chains requires a massive
rearrangement of half the molecules (Fig. 9). This involves
losing hydrogen bonding before gaining stabilization from
the dispersion forces between the steroid backbones.
Obtaining the anhydrate structure shows that desolvation in-
volves such a substantial rearrangement of the molecules
that it requires a nucleation and growth mechanism which
will be very dependent on how the real crystals differ from
the infinite perfect crystals used in the calculations. The
desolvation studies show that when in microcrystalline form,
water is often lost from BES·0.5H2O in two stages, though
this is dependent on sample and conditions. When
BES·0.5H2O is in single crystal form the water molecules ap-
pear to be bound more tightly and desolvation appears to oc-
cur in one step at 173.5 °C. The dissimilarity of the two struc-
tures could mean that intermediate forms, such as transient
lower hydrates, BES(am) or BES Form II are also involved in a
particle-size and structural-purity-dependent mechanism. It
is also possible to rationalize the observation of an apparent
two stage desolvation for BES·0.5H2O (ref. 14 and 16) (and
BES·0.5MeOH (ref. 17)) as surface solvent being lost when
there is a high surface area in microcrystalline form.
Fig. 9 Comparison of the common packings of BES Form I (coloured by element), BES·0.5H2O (cyan) and BES·PrOH (violet). (a) Shows the
overlaid chain, (b) shows the chain and hydrogen bonded solvent (second BES molecule in the case of BES Form I), (c) shows the surrounding
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Conclusions
The crystal structure of anhydrous 17-β-estradiol has finally
been established by SCXRD, along with those of an acetoni-
trile solvate and more modern determinations of the struc-
tures of the hemihydrate, and two alcohol solvates. 17-β-
estradiol has a high affinity for water, making crystallization
of the anhydrate challenging and the dehydration process de-
pendent on the particle size and structural defects.
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